Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
With its novel antifungal candidate rezafungin now at the US Food and Drug Administration for review, Cidara Therapeutics, Inc. is monetizing its asset, getting $30m up front from Melinta Therapeutics, Inc. for US commercial rights to the once-weekly echinocandin intended to treat candidemia and invasive candidiasis
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?